FDA Announces Public Meeting on Reauthorization of Medical Device User Fee Amendments (July 7, 2026)

Source Information

• Source agency: U.S. Food and Drug Administration (FDA)
• Original date: July 7, 2026
• Publication date on this site: July 8, 2026, 09:00
• Original link: https://www.fda.gov/medical-devices/medical-devices-news-and-events/register-fdas-public-meeting-reauthorization-medical-device-user-fee-amendments-08052026

FDA has announced that it will hold a public meeting on August 5, 2026 on the reauthorization of the Medical Device User Fee Amendments (MDUFA), to discuss proposed MDUFA recommendations for fiscal years 2028 to 2032. The meeting has implications for device review fees, review resources and market-entry pathway planning.

Full Translation of the Original Announcement

According to the FDA announcement, the agency will convene a public meeting on August 5, 2026 on the reauthorization of the Medical Device User Fee Amendments to discuss proposed MDUFA recommendations for fiscal years 2028 through 2032. MDUFA is a core funding and performance mechanism of the U.S. medical device review system. It authorizes FDA to collect fees for relevant submissions, and the resulting resources support review capacity, communication mechanisms, review-time management and program operations.

The current MDUFA authorization expires on September 30, 2027. FDA therefore needs to engage with industry, the public and other stakeholders on the next-phase recommendations before the new authorization cycle begins. Discussions at such meetings typically address the user fee structure, review performance goals, submission types, support for innovative products, arrangements for communication meetings, resource allocation, and the commitment mechanisms between FDA and industry.

For companies preparing to enter the U.S. market, although this type of meeting is not a product-specific registration guidance document, it will shape the FDA review environment over the coming years. When preparing 510(k), De Novo, PMA, Q-Submission or other premarket communications, companies should incorporate MDUFA fees, review goals and FDA communication mechanisms into project budgets and timelines.

AIMEILI Regulatory Interpretation

AIMEILI Regulatory Affairs views the MDUFA reauthorization as more than a matter of FDA user fees and meeting scheduling: it bears directly on U.S. medical device review resources, communication mechanisms and program timelines over the next several years. For manufacturers, user fees are not merely a cost line item but an institutional signal linked to review performance goals, the cadence of Q-Submission interactions, support for innovative devices, the allocation of review resources and the stability of premarket pathways.

Companies preparing to enter the U.S. market should build the MDUFA cycle into their medium- and long-term registration planning. This applies in particular to 510(k), De Novo, PMA, Breakthrough Device, digital health and AI-enabled medical device projects. Planning should not be back-scheduled solely on the basis of current fees and current review experience; companies should continuously monitor whether a new authorization cycle adjusts the fee structure, review commitments, communication windows or the way submission types are managed. Budgets, testing plans, FDA communication milestones and commercial launch dates should be managed as one integrated project system.

AIMEILI recommends that companies establish a "pathway–fee–evidence–communication" matrix at the start of any U.S. project. This matrix should define the applicable submission type, estimated official fees, key testing requirements, whether a Pre-Submission is needed, likely additional information requests and internal decision points. This approach not only reduces project uncertainty but also helps management understand why U.S. registration is not simply a matter of submitting documents, but a market-access program requiring sustained investment.

Business Impact

For companies planning to submit 510(k), De Novo, PMA, Q-Submission or other U.S. registration projects, user fee reauthorization is not only a question of cost. It may also affect review resources, communication mechanisms, performance goals and project scheduling. Companies should monitor the final fee structure, review-time commitments, support mechanisms for innovative devices and FDA–industry communication arrangements, and should avoid relying on outdated assumptions in budgets and launch timelines.

Compliance Actions for Manufacturers

• Confirm whether the update affects existing registration pathways, certificate maintenance or post-market obligations.
• Verify technical documentation, labels and instructions for use, quality system arrangements and local responsible-party arrangements for the target countries.
• Establish change impact assessments and regulatory update tracking records for marketed products.
• Where necessary, archive the official source text, the translated interpretation and internal action items to support subsequent audits and project reviews.

Scope and Limitations

Content prepared by: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI Medical Device International Registration Project Team. Sourcing principle: official regulatory authorities, international organizations, standards bodies and publicly available regulatory materials are prioritized; industry media and project experience are used only as supporting judgment. Scope: this article is intended for preliminary understanding, document preparation and project planning. It does not replace the formal requirements of the relevant regulatory authority, testing conclusions or legal opinions.